(Q67762011)

English

Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin ?-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069)

scientific article published on 01 January 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin ?-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069) (English)

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

1 reference

based on heuristic

inferred from title

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

M. Binger

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1742848

13 November 2022

P. Workman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1742848

13 November 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1742848

13 November 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

full work available at URL

http://link.springer.com/content/pdf/10.1007/BF00686334.pdf

Portable Document Format

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

http://link.springer.com/article/10.1007/BF00686334/fulltext.html

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

http://link.springer.com/content/pdf/10.1007/BF00686334

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

37-47

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1742848%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

https://scigraph.springernature.com/pub.10.1007/bf00686334

0 references

Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of the aziridine moiety of RSU-1069 with nucleotides and inorganic phosphate. Implications for alkylation of DNA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxic cells as specific drug targets for chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fate of free bis(beta-chloroethyl)-amine in blood serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively ac

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/1742848

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Journal of the National Cancer Institute

11

39

539

author name string

RF Kallman

publication date

1967

1 reference

10.1007/BF00686334

https://api.crossref.org/works/10.1007/BF00686334

13 November 2022

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67762011&oldid=2154328837"